Biomica, a Rehovot, Israel-based clinical-stage biopharmaceutical company, raised $20M in funding.
The round was led by a $10M investment from Shanghai Healthcare Capital. Following the investment, SHC holds 20% of the share capital in Biomica on a fully-diluted basis. Evogene also invested $10M in the current financing round.
The company intends to use the funds to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial, scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of inflammatory bowel disease (IBD), as well as advance additional programs.
Biomica is a clinical stage biopharmaceutical company developing microbiome-based therapeutics utilizing MicroBoost AI tech-engine, licensed from Evogene. The company works to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. It is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN).
FinSMEs
27/04/2023